生产企业：Generate:Biomedicines
GB-0895 is an anti-TSLP monoclonal antibody developed by Generate:Biomedicines, currently in Phase III clinical trials for severe asthma with planned expansion into COPD.
GB-0895 is an anti-TSLP monoclonal antibody developed by Generate:Biomedicines, currently in Phase III clinical trials for severe asthma with planned expansion into COPD.
GB-0895 is an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody that targets and neutralizes TSLP, a key epithelial cytokine involved in initiating and perpetuating type 2 inflammatory responses in asthma and COPD.
GB-0895 is in Phase III clinical development for severe asthma. Phase I data supported direct advancement to Phase III, showing strong biomarker modulation and comparable or superior target occupancy to tezepelumab. The company also plans to propose a direct Phase III trial in COPD.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
